Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 8-K

INOVIO PHARMACEUTICALS, INC.

Form 8-K February 26, 2014

#### **UNITED STATES**

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

## **CURRENT REPORT**

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 26, 2014

# INOVIO PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction

001-14888 (Commission 33-0969592 (I.R.S. Employer

of incorporation)

File Number)

**Identification No.)** 

## Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 8-K

## 1787 Sentry Parkway West

**Building 18, Suite 400** 

Blue Bell, Pennsylvania 19422
(Address of principal executive offices) (Zip Code)
Registrant s telephone number, including area code: (267) 440-4200

### N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- "Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 8-K

#### Item 8.01. Other Events.

Inovio Pharmaceuticals, Inc. (the Company) is filing this Form 8-K current report to provide certain information as an update to the information provided in the Company s previous periodic filings with the Securities and Exchange Commission (the SEC) in order to reflect recent business developments. A summary description of the Company s business is attached hereto as Exhibits 99.1 and is incorporated herein by reference. This Form 8-K, including the exhibits hereto, should be read in conjunction with the Company s Form 10-K annual report for the year ended December 31, 2012, the Company s Form 10-Q quarterly reports for the quarters ended March 31, 2013, June 30, 2013 and September 30, 2013 and the Company s Form 8-K current reports.

On February 26, 2014, the Company issued a press release announcing its intention to offer and sell shares of its common stock in an underwritten public offering, subject to market conditions and other factors, pursuant to the Company s effective Registration Statement on Form S-3 (File No. 333-193698). The full text of the press release issued in connection with the announcement is attached to this Form 8-K as Exhibit 99.2 and is incorporated herein by reference.

# <u>Item 9.01.</u> <u>Financial Statements and Exhibits.</u>

Exhibit

No. Exhibit Description

99.1 Updated Summary Business Description

99.2 Inovio Pharmaceuticals, Inc. Press Release dated February 26, 2014

## **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INOVIO PHARMACEUTICALS, INC.

By: /s/ Peter Kies Peter Kies, Chief Financial Officer

Date: February 26, 2014